Positive FDA Feedback on Phase 2 Study Design

Summary by AI BETAClose X

Arecor Therapeutics PLC received positive feedback from the FDA regarding its Phase 2 clinical study design for AT278, an ultra-concentrated (500 U/mL) and ultra-rapid acting insulin, in combination with an Automated Insulin Delivery (AID) system. The study, expected to enroll less than 100 subjects with type 1 and type 2 diabetes, will use Time-in-Range (TIR) as the primary efficacy endpoint. This allows for a shorter, six-week dosing period, compared to the minimum twelve weeks required for HbA1c. Arecor plans to submit the Phase 2 IND to the FDA during 2026 and aims to commence the Phase 2 study later that year. The comparator will be NovoLog® (100 U/mL).

Disclaimer*

UK 100

Latest directors dealings